Marieke J A Verhagen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Marieke J A Verhagen has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
- Saskia E. M. Schols
Department of Hematology Radboud University Medical Center Nijmegen The Netherlands
2 shared publications - Lars L. F. G. Valke
Department of Hematology Radboud University Medical Center Nijmegen The Netherlands
1 shared publication - Sanna R. Rijpma
Department of Laboratory Medicine , Laboratory of Hematology, Radboudumc , Nijmegen , The Netherlands
1 shared publication
Latest Publications
- Open Access
- 1 January 2025
- Published by Haemnet Ltd in The Journal of Haemophilia Practice
- Vol. 12 (1) , 82-86
Acquired haemophilia A: Balancing on the edge of haemostasis – Case series
Introduction: Emicizumab has recently been investigated for prophylactic use in patients with acquired haemophilia A. While it shows promising results in effectively reducing bleeding episodes, there remains a very delicate question concerning the risk of thromboembolic events. Recently published prospective studies reported thrombotic events in 4% to 8% of cases. However, these studies excluded patients with an increased thrombotic risk or those undergoing treatment for a thromboembolic disease, situations frequently occurring in this elderly patient group. Therefore, we urge clinicians to critically assess which patients would benefit from emicizumab treatment and which would not. Case series: Here, we present a case series from a Dutch haemophilia treatment centre that highlights the complexity of patients currently managed with acquired haemophilia A. The series discusses individual patient characteristics, underlying comorbidities, and responses to initiated therapy with bypassing agents and immunosuppressive therapy. The pros and cons of emicizumab therapy in these individual patients are discussed. Discussion: We suggest considering the use of emicizumab in patients with acquired haemophilia A through a personalised approach. This approach involves assessing thrombotic risk on one hand and focusing on controlling bleeding on the other. It should account for the need to rapidly eradicate the inhibitor in cases of acute bleeding necessitating bypassing agents. Alternatively, it should consider the possibility of postponing or reducing immunosuppressive therapy in frail patients without overt bleeding, for whom emicizumab presents an ideal prophylactic option.
- 1 January 2025
- Published by Haemnet Ltd in The Journal of Haemophilia Practice
- Vol. 12 (1) , 82-86
Open AccessAcquired haemophilia A: Balancing on the edge of haemostasis – Case series
Introduction: Emicizumab has recently been investigated for prophylactic use in patients with acquired haemophilia A. While it shows promising results in effectively reducing bleeding episodes, there remains a very delicate question concerning the risk of thromboembolic events. Recently published prospective studies reported thrombotic events in 4% to 8% of cases. However, these studies excluded patients with an increased thrombotic risk or those undergoing treatment for a thromboembolic disease, situations frequently occurring in this elderly patient group. Therefore, we urge clinicians to critically assess which patients would benefit from emicizumab treatment and which would not. Case series: Here, we present a case series from a Dutch haemophilia treatment centre that highlights the complexity of patients currently managed with acquired haemophilia A. The series discusses individual patient characteristics, underlying comorbidities, and responses to initiated therapy with bypassing agents and immunosuppressive therapy. The pros and cons of emicizumab therapy in these individual patients are discussed. Discussion: We suggest considering the use of emicizumab in patients with acquired haemophilia A through a personalised approach. This approach involves assessing thrombotic risk on one hand and focusing on controlling bleeding on the other. It should account for the need to rapidly eradicate the inhibitor in cases of acute bleeding necessitating bypassing agents. Alternatively, it should consider the possibility of postponing or reducing immunosuppressive therapy in frail patients without overt bleeding, for whom emicizumab presents an ideal prophylactic option.
- Open Access
- 28 January 2022
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 20 (4) , 794-805
Thrombin generation for monitoring hemostatic therapy in hemophilia A: A narrative review
- 28 January 2022
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 20 (4) , 794-805
Open AccessThrombin generation for monitoring hemostatic therapy in hemophilia A: A narrative review